Overview Dividends

(LXRX) Lexicon Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5288723027

Sotagliflozin, LX9211, LX9851

Biotechnology
Market Cap in USD: 447m
IPO / Inception: 2000-04-07
Return 12m vs S&P 500: 25.4%

EPS (Earnings per Share)

EPS (Earnings per Share) of LXRX over the last years for every Quarter: "2020-12": -0.04, "2021-03": -0.15, "2021-06": -0.13, "2021-09": -0.16, "2021-12": -0.17, "2022-03": -0.16, "2022-06": -0.16, "2022-09": -0.13, "2022-12": -0.16, "2023-03": -0.17, "2023-06": -0.22, "2023-09": -0.21, "2023-12": -0.2, "2024-03": -0.2, "2024-06": -0.17, "2024-09": -0.18, "2024-12": -0.09, "2025-03": -0.07, "2025-06": 0.01, "2025-09": -0.04, "2025-12": 0,
EPS CAGR: 35.28%
EPS Trend: 68.1%
Last SUE: 1.93
Qual. Beats: 1

Revenue

Revenue of LXRX over the last years for every Quarter: 2020-12: 0.199, 2021-03: 0.027, 2021-06: 0.234, 2021-09: 0.023, 2021-12: 0.014, 2022-03: 0.037, 2022-06: 0.035, 2022-09: 0.039, 2022-12: 0.028, 2023-03: 0.024, 2023-06: 0.317, 2023-09: 0.162, 2023-12: 0.702, 2024-03: 1.13, 2024-06: 1.647, 2024-09: 1.75, 2024-12: 26.554, 2025-03: 1.262, 2025-06: 28.866, 2025-09: 14.182, 2025-12: null,
Rev. CAGR: 533.13%
Rev. Trend: 93.4%
Last SUE: 0.90
Qual. Beats: 2

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 77.7%
Value at Risk 5%th 108%
Relative Tail Risk -15.33%
Reward TTM
Sharpe Ratio 1.02
Alpha 34.37
CAGR/Max DD -0.20
Character TTM
Hurst Exponent 0.495
Beta 0.861
Beta Downside 1.015
Drawdowns 3y
Max DD 91.83%
Mean DD 53.41%
Median DD 56.98%

Description: LXRX Lexicon Pharmaceuticals December 29, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) is a U.S.-based biotech that develops oral small-molecule therapies. Its lead asset, sotagliflozin, is an SGLT-1/2 inhibitor approved for reducing cardiovascular death, heart-failure hospitalizations, and urgent visits in patients with heart failure, type 2 diabetes, or chronic kidney disease. The pipeline includes sotagliflozin in Phase 3 for hypertrophic cardiomyopathy and type 1 diabetes, LX9211 (Phase II completed for neuropathic pain), and LX9851 (obesity and cardiometabolic risk). The company partners with Viatris and Bristol-Myers Squibb for commercialization and co-development.

Key metrics (as of the latest 10-Q): market capitalization ≈ $1.2 B, cash and equivalents ≈ $350 M, giving ~12-month runway at current burn (~$30 M/quarter). The SGLT-inhibitor class is projected to grow > 10 % CAGR through 2028, driven by expanding indications beyond diabetes. Lexicon’s upcoming catalysts are the Phase 3 readout for HCM (Q3 2025) and potential FDA action on its obesity candidate LX9851, which could tap the $70 B global obesity-treatment market.

For a data-driven assessment of how Lexicon’s valuation stacks up against sector peers, you might find ValueRay’s analyst tools useful.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-68.6m TTM) > 0 and > 6% of Revenue (6% = 4.25m TTM)
FCFTA -0.35 (>2.0%) and ΔFCFTA 29.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 142.3% (prev 4448 %; Δ -4305 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.35 (>3.0%) and CFO -72.1m <= Net Income -68.6m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 5.64 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (363.4m) change vs 12m ago 0.53% (target <= -2.0% for YES)
Gross Margin 63.05% (prev -191.5%; Δ 254.6pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 26.89% (prev 1.63%; Δ 25.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -4.81 (EBITDA TTM -48.3m / Interest Expense TTM 10.2m) >= 6 (WARN >= 3)

Altman Z'' -54.24

(A) 0.49 = (Total Current Assets 122.5m - Total Current Liabilities 21.7m) / Total Assets 205.9m
(B) -9.72 = Retained Earnings (Balance) -2.00b / Total Assets 205.9m
warn (B) unusual magnitude: -9.72 — check mapping/units
(C) -0.19 = EBIT TTM -48.9m / Avg Total Assets 263.5m
(D) -23.34 = Book Value of Equity -2.00b / Total Liabilities 85.8m
Total Rating: -54.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 36.30

1. Piotroski 1.0pt
2. FCF Yield -18.65%
3. FCF Margin data missing
4. Debt/Equity 0.48
5. Debt/Ebitda -0.18
6. ROIC - WACC (= -79.83)%
7. RoE -52.90%
8. Rev. Trend 93.42%
9. EPS Trend 68.11%

What is the price of LXRX shares?

As of January 02, 2026, the stock is trading at USD 1.15 with a total of 1,791,175 shares traded.
Over the past week, the price has changed by -6.50%, over one month by -15.44%, over three months by -18.44% and over the past year by +47.99%.

Is LXRX a buy, sell or hold?

Lexicon Pharmaceuticals has received a consensus analysts rating of 3.80. Therefor, it is recommend to hold LXRX.
  • Strong Buy: 1
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the LXRX price?

Issuer Target Up/Down from current
Wallstreet Target Price 2.9 150.4%
Analysts Target Price 2.9 150.4%
ValueRay Target Price 1.1 -2.6%

LXRX Fundamental Data Overview December 28, 2025

Market Cap USD = 447.0m (447.0m USD * 1.0 USD.USD)
P/S = 6.3076
P/B = 3.7199
P/EG = -0.14
Beta = 0.97
Revenue TTM = 70.9m USD
EBIT TTM = -48.9m USD
EBITDA TTM = -48.3m USD
Long Term Debt = 56.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.64m USD (from shortTermDebt, last quarter)
Debt = 58.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.49m USD (from netDebt column, last quarter)
Enterprise Value = 389.2m USD (447.0m + Debt 58.1m - CCE 116.0m)
Interest Coverage Ratio = -4.81 (Ebit TTM -48.9m / Interest Expense TTM 10.2m)
FCF Yield = -18.65% (FCF TTM -72.6m / Enterprise Value 389.2m)
FCF Margin = -102.4% (FCF TTM -72.6m / Revenue TTM 70.9m)
Net Margin = -96.77% (Net Income TTM -68.6m / Revenue TTM 70.9m)
Gross Margin = 63.05% ((Revenue TTM 70.9m - Cost of Revenue TTM 26.2m) / Revenue TTM)
Gross Margin QoQ = 99.93% (prev 99.28%)
Tobins Q-Ratio = 1.89 (Enterprise Value 389.2m / Total Assets 205.9m)
Interest Expense / Debt = 3.71% (Interest Expense 2.15m / Debt 58.1m)
Taxrate = 100.0% (out of range, set to none) (-200.4m / -200.4m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 5.64 (Total Current Assets 122.5m / Total Current Liabilities 21.7m)
Debt / Equity = 0.48 (Debt 58.1m / totalStockholderEquity, last quarter 120.2m)
Debt / EBITDA = -0.18 (negative EBITDA) (Net Debt 8.49m / EBITDA -48.3m)
Debt / FCF = -0.12 (negative FCF - burning cash) (Net Debt 8.49m / FCF TTM -72.6m)
Total Stockholder Equity = 129.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.30% (Net Income -68.6m / Total Assets 205.9m)
RoE = -52.90% (Net Income TTM -68.6m / Total Stockholder Equity 129.6m)
RoCE = -26.29% (EBIT -48.9m / Capital Employed (Equity 129.6m + L.T.Debt 56.5m))
RoIC = -71.70% (negative operating profit) (EBIT -48.9m / (Assets 205.9m - Curr.Liab 21.7m - Cash 116.0m))
WACC = 8.13% (E(447.0m)/V(505.1m) * Re(9.19%) + (debt cost/tax rate unavailable))
Discount Rate = 9.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 38.84%
Fair Price DCF = unknown (Cash Flow -72.6m)
EPS Correlation: 68.11 | EPS CAGR: 35.28% | SUE: 1.93 | # QB: 1
Revenue Correlation: 93.42 | Revenue CAGR: 533.1% | SUE: 0.90 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-0.07 | Chg30d=+0.035 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.26 | Chg30d=+0.000 | Revisions Net=+4 | Growth EPS=-55.5% | Growth Revenue=-68.5%

Additional Sources for LXRX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle